PE20020875A1 - Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interes - Google Patents
Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interesInfo
- Publication number
- PE20020875A1 PE20020875A1 PE2002000083A PE2002000083A PE20020875A1 PE 20020875 A1 PE20020875 A1 PE 20020875A1 PE 2002000083 A PE2002000083 A PE 2002000083A PE 2002000083 A PE2002000083 A PE 2002000083A PE 20020875 A1 PE20020875 A1 PE 20020875A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- dna
- peptides
- refers
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108020004705 Codon Proteins 0.000 abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 102000007625 Hirudins Human genes 0.000 abstract 1
- 108010007267 Hirudins Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241001138401 Kluyveromyces lactis Species 0.000 abstract 1
- 108010076181 Proinsulin Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 1
- 229940006607 hirudin Drugs 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Abstract
SE REFIERE A ADN Px-Sx-Bn-(ZR)-PEPTIDO DE TRANSPORTE-(Z1Z2)-PROTEINA(Y)-(Z1Z2)-PROTEINA(Ym)-T, QUE CODIFICA UN PEPTIDO DE TRANSPORTE UNIDO POR MEDIO DE UNA SECUENCIA Z1Z2 A UNA SEGUNDA PROTEINA QUE SE UNE POR Z1Z2 A UNA PROTEINA Y1 QUE CORRESPONDE A Y, O PUEDE SER DIFERENTE DE Y; Px ES ADN PROMOTOR; Sx ES ADN QUE CODIFICA UNA SECUENCIA SENAL; Bn ES 1-15 AMINOACIDOS CODIFICABLES GENETICAMENTE O UN ENLACE; Z, Z1, Z2 SON UN CODON DE UN AMINOACIDO TAL COMO Lys, Arg; Ym ES ADN QUE CODIFICA UNA PROTEINA QUE PUEDE SER PRODUCIDA POR UNA LEVADURA (m ES 1-5) O ES UN ENLACE (m=0); R ES UN CODON DE ARGININA; EL PEPTIDO DE TRANSPORTE ES VARIANTES DE HIRUDINA QUE PUEDE SER TRANSPORTADO DE FORMA EFICIENTE Y PUEDE TRASPASAR LAS MEMBRANAS, MEJORA LA TASA DE SECRECION DE Y, Ym; PROTEINA Y ES ADN QUE CODIFICA A UN PEPTIDO (PROINSULINA, INTERLEUQUINAS, LINFOQUINAS, INTERFERONES, FACTORES DERIVADOS DE LOS SISTEMAS DE COAGULACION) QUE PUEDE SER PRODUCIDA Y SEGREGADA POR UNA LEVADURA CUYA ACTIVIDAD BIOLOGICA CUANDO Ym NO ES UN ENLACE, NO ESTA IMPEDIDA POR UNA EXTENSION DE UN DIPEPTIDO BASICO O PERMITE LA DEGRADACION DE LA EXTENSION POR CARBOXIPEPTIDASAS; T ES ADN SIN TRADUCIR VENTAJAS PARA LA EXPRESION. TAMBIEN SE REFIERE A PROTEINAS, VECTOR, PLASMIDO, CELULA COMO S CEREVISIAE, K. LACTIS, H. POLIMORPHA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA FERMENTAR. LA ELECCION DEL SISTEMA VECTOR HOSPEDANTE ES IMPORTANTE PARA EL RENDIMIENTO Y EL TRATAMIENTO QUIMICO MAS SIMPLE DE LA PROTEINA DE INTERES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10108100A DE10108100A1 (de) | 2001-02-20 | 2001-02-20 | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020875A1 true PE20020875A1 (es) | 2002-10-31 |
Family
ID=7674831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000083A PE20020875A1 (es) | 2001-02-20 | 2002-02-06 | Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interes |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1364030B1 (es) |
| JP (1) | JP4243103B2 (es) |
| KR (1) | KR100858008B1 (es) |
| CN (1) | CN100575493C (es) |
| AT (1) | ATE320498T1 (es) |
| AU (1) | AU2002247696B2 (es) |
| BR (1) | BR0207385A (es) |
| CA (1) | CA2438935C (es) |
| CY (1) | CY1105696T1 (es) |
| DE (2) | DE10108100A1 (es) |
| DK (1) | DK1364030T3 (es) |
| ES (1) | ES2258619T3 (es) |
| HK (1) | HK1065818A1 (es) |
| IL (1) | IL157415A0 (es) |
| MX (1) | MXPA03007115A (es) |
| NO (1) | NO331375B1 (es) |
| NZ (1) | NZ527641A (es) |
| PE (1) | PE20020875A1 (es) |
| PT (1) | PT1364030E (es) |
| WO (1) | WO2002066628A2 (es) |
| ZA (1) | ZA200305867B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060233808A1 (en) * | 2003-04-04 | 2006-10-19 | David Deperthes | Peptabody for cancer treatment |
| DE102006031955A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| PT2349324T (pt) | 2008-10-17 | 2017-12-06 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| EP2498801B1 (de) | 2009-11-13 | 2018-01-24 | Sanofi-Aventis Deutschland GmbH | HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN |
| EP2611458B1 (en) | 2010-08-30 | 2016-09-21 | Sanofi-Aventis Deutschland GmbH | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN108866205A (zh) * | 2018-07-25 | 2018-11-23 | 中国食品药品检定研究院 | 基于分子生物学方法鉴别菲牛蛭的特异性引物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE58906966D1 (de) * | 1988-06-23 | 1994-03-24 | Hoechst Ag | Mini-Proinsulin, seine Herstellung und Verwendung. |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| FI92601C (fi) | 1992-03-11 | 1994-12-12 | Marja Makarow | Menetelmä hyötyproteiinien erittämiseksi hiivoista |
-
2001
- 2001-02-20 DE DE10108100A patent/DE10108100A1/de not_active Withdrawn
-
2002
- 2002-02-06 PE PE2002000083A patent/PE20020875A1/es not_active Application Discontinuation
- 2002-02-08 KR KR1020037010738A patent/KR100858008B1/ko not_active IP Right Cessation
- 2002-02-08 PT PT02716745T patent/PT1364030E/pt unknown
- 2002-02-08 AU AU2002247696A patent/AU2002247696B2/en not_active Ceased
- 2002-02-08 JP JP2002566335A patent/JP4243103B2/ja not_active Expired - Fee Related
- 2002-02-08 WO PCT/EP2002/001306 patent/WO2002066628A2/en active IP Right Grant
- 2002-02-08 DE DE60209883T patent/DE60209883T2/de not_active Expired - Lifetime
- 2002-02-08 MX MXPA03007115A patent/MXPA03007115A/es active IP Right Grant
- 2002-02-08 BR BR0207385-4A patent/BR0207385A/pt not_active IP Right Cessation
- 2002-02-08 NZ NZ527641A patent/NZ527641A/en not_active IP Right Cessation
- 2002-02-08 IL IL15741502A patent/IL157415A0/xx not_active IP Right Cessation
- 2002-02-08 DK DK02716745T patent/DK1364030T3/da active
- 2002-02-08 CN CN02806848A patent/CN100575493C/zh not_active Expired - Fee Related
- 2002-02-08 CA CA2438935A patent/CA2438935C/en not_active Expired - Fee Related
- 2002-02-08 AT AT02716745T patent/ATE320498T1/de active
- 2002-02-08 ES ES02716745T patent/ES2258619T3/es not_active Expired - Lifetime
- 2002-02-08 EP EP02716745A patent/EP1364030B1/en not_active Expired - Lifetime
-
2003
- 2003-07-30 ZA ZA200305867A patent/ZA200305867B/en unknown
- 2003-08-19 NO NO20033671A patent/NO331375B1/no not_active IP Right Cessation
-
2004
- 2004-11-01 HK HK04108554.7A patent/HK1065818A1/xx not_active IP Right Cessation
-
2006
- 2006-06-07 CY CY20061100751T patent/CY1105696T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1364030T3 (da) | 2006-07-17 |
| NO331375B1 (no) | 2011-12-12 |
| ATE320498T1 (de) | 2006-04-15 |
| BR0207385A (pt) | 2004-02-10 |
| IL157415A0 (en) | 2004-03-28 |
| DE60209883T2 (de) | 2006-09-07 |
| WO2002066628A2 (en) | 2002-08-29 |
| MXPA03007115A (es) | 2003-11-18 |
| KR20030074832A (ko) | 2003-09-19 |
| CY1105696T1 (el) | 2010-12-22 |
| EP1364030A2 (en) | 2003-11-26 |
| EP1364030B1 (en) | 2006-03-15 |
| AU2002247696B2 (en) | 2006-10-12 |
| CN1527882A (zh) | 2004-09-08 |
| CN100575493C (zh) | 2009-12-30 |
| DE60209883D1 (de) | 2006-05-11 |
| HK1065818A1 (en) | 2005-03-04 |
| PT1364030E (pt) | 2006-05-31 |
| JP2004518442A (ja) | 2004-06-24 |
| WO2002066628A3 (en) | 2002-11-14 |
| ZA200305867B (en) | 2004-06-29 |
| NZ527641A (en) | 2005-03-24 |
| NO20033671L (no) | 2003-10-17 |
| DE10108100A1 (de) | 2002-08-29 |
| JP4243103B2 (ja) | 2009-03-25 |
| KR100858008B1 (ko) | 2008-09-11 |
| CA2438935C (en) | 2012-01-24 |
| ES2258619T3 (es) | 2006-09-01 |
| CA2438935A1 (en) | 2002-08-29 |
| NO20033671D0 (no) | 2003-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11518794B2 (en) | Synthesis method for liraglutide with low racemate impurity | |
| PE20020875A1 (es) | Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interes | |
| Agerberth et al. | Amino acid sequence of PR‐39: isolation from pig intestine of a new member of the family of proline‐arginine‐rich antibacterial peptides | |
| EP1392717A4 (en) | FAST CLEAVABLE SUMOFUSION PROTEIN EXPRESSION SYSTEM FOR HEAVY-TO-EXPRESS PROTEINS | |
| DE602006020617D1 (de) | Lactoferrin-peptide, geeignet als in die zelle eindringende peptide | |
| NO965411L (no) | N-terminalt forlengede proteiner uttrykt i gjær | |
| Knauer et al. | Sustainable peptide synthesis enabled by a transient protecting group | |
| CN111670194B (zh) | 制备胰高血糖素肽 | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| CY1106681T1 (el) | Διεργασια παραγωγης του ανασυνδyασμενου πλακουντιου αυξητικου παραγοντα | |
| DE602007011616D1 (de) | Verfahren zur herstellung von oligopeptiden | |
| ATE490266T1 (de) | In zellen eindringende peptide als träger für moleküle | |
| DE69233245D1 (de) | Verfahren zur Herstellung von Peptiden | |
| Vernieri et al. | An optimized Fmoc synthesis of human defensin 5 | |
| MXPA05012336A (es) | Procedimiento para producir una proteina dirigida a un plastidio en celulas vegetales. | |
| GB201102700D0 (en) | Protein secretion | |
| BUDZYNSKI et al. | Solid Phase Synthesis of Human Fibrinopeptides A and Bf | |
| US20240076311A1 (en) | Method for synthesizing peptide thioesters and head-to-tail amide cyclic peptide thereof | |
| AR124188A1 (es) | Antígenos nuevos | |
| WO2003064446A3 (en) | Plasma protein-binding peptides from bacterial curli | |
| Zhang et al. | Two short D-Phe-containing cysteine-free conopeptides from conus marmoreus | |
| Tanaka et al. | Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins | |
| Quagliariello et al. | Department of Molecular Biology, The Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK | |
| Agerberth et al. | Ammo acid sequence of PR-39. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |